GSK Expands Share Buyback Program with Recent Purchase

GlaxoSmithKline ( (GB:GSK) ) has shared an announcement.

GSK has announced the repurchase of 167,000 of its own shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction is part of a larger strategy initiated on September 30, 2025, which has seen the company buy back a total of 8,830,000 shares. The repurchased shares will be held as treasury shares, impacting the company’s voting rights and share distribution, with 6.31% of voting rights now attributable to treasury shares. This move reflects GSK’s efforts to manage its capital structure and return value to shareholders.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The company’s robust growth in specialty medicines and successful R&D efforts contribute positively. Technical analysis supports a bullish outlook, while valuation remains reasonable with an attractive dividend yield. Challenges in the U.S. vaccines market and clinical trial delays are noted but do not significantly detract from the overall positive outlook.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company operating in the pharmaceutical industry. It is primarily focused on the development and manufacturing of medicines, vaccines, and consumer healthcare products.

Average Trading Volume: 8,397,561

Technical Sentiment Signal: Buy

Current Market Cap: £73.27B

See more data about GSK stock on TipRanks’ Stock Analysis page.